Brief: CanSino Biologics Says Supplemental Drug Application For Menhycia Accepted By NMPA China
26/11/2024 10:09
Nov 26 (Reuters) - CanSino Biologics Inc 688185.SS :
* ACCEPTANCE OF SUPPLEMENTAL DRUG APPLICATION FOR MENHYCIA
BY NMPA
CHINA
Further company coverage: 688185.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cansino Biologics
See all newsBrief: CanSino Biologics Says China's NMPA Granted Priority Review Status To NDA For TD5CP Adolescent, Adult
Brief: CanSino Biologics Reports Widened Net Loss For Q1
Brief: CanSino Biologics Says 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Prelim 2025 Net Profit At 27.9 Million Yuan
Brief: CanSino Biologics Expects To Have Returned to Net Profit In 2025